How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

678 results for

Sibutramine

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

61. Contributory Risk and Management of Comorbidities of Hypertension, Obesity, Diabetes Mellitus, Hyperlipidemia, and Metabolic Syndrome in Chronic Heart Failure: A Scientific Statement From the American Heart Association Full Text available with Trip Pro

committee cautions against the use of ephedra, sibutramine, and other weight-loss prepara- tions because they may contribute to the development of HF and should be avoided. 8 Currently, given the above concerns and the lack of evidence on intentional weight loss in HF, the 2009 AHA scientific statement on promoting self-care in individu- als with HF suggests weight loss only if the BMI is >40 kg/m 2 . 249 If the BMI is 35 kg/m 2 , gastrointestinal surgery may be an option. Additionally, in patients (...) or physical activity for the pur- poses of improving health-related QOL or managing comorbidities such as diabetes mellitus, hypertension, or sleep apnea may be reasonable in obese patients with HF (Class IIb; Level of Evidence C). 2. Sibutramine or ephedra weight loss prepara- tions are contraindicated in HF . Use of ephedra weight-loss preparations may contribute to the development of HF and should be avoided (Class III: Harm; Level of Evidence C). No Data Weight reduction, including with bariatric

2016 American Heart Association

62. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for Comprehensive Medical Care of Patients with Obesity

; RR = rel- ative risk; RYGB = Roux-en-Y gastric bypass; SAD = sagittal abdominal diameter; SBP = systolic blood pres- sure; SCOUT = Sibutramine Cardiovascular Outcome Trial; SG = sleeve gastrectomy; SHBG = sex hormone- binding globulin; SIEDY = Structured Interview on Erectile Dysfunction; SNRI = serotonin-norepinephrine reuptake inhibitors; SOS = Swedish Obese Subjects; SS = surveillance study; SSRI = selective serotonin reuptake inhibitors; STORM = Sibutramine Trial on Obesity Reduction

2016 American Association of Clinical Endocrinologists

63. Vagal Nerve Blockade for Obesity: VBLOC Therapy Using the Maestro RC2 Device

Apr 13]. Available from: National Heart, Lung, and Blood Institute. Aim for a healthy weight: key recommendations [Internet]. Bethesda (MD): The Institute; [2014]. [cited 2015 Apr 13]. Available from: Johansson K, Neovius K, DeSantis SM, Rossner S, Neovius M. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis. Obes Rev. 2009 Sep;10(5):564-75. Bray GA. Medications for weight reduction. Med Clin North Am. 2011 Sep;95(5):989-1008

2015 CADTH - Issues in Emerging Health Technologies

64. Vagal Nerve Blockade for Obesity: VBLOC Therapy Using the Maestro RC2 Device

Apr 13]. Available from: National Heart, Lung, and Blood Institute. Aim for a healthy weight: key recommendations [Internet]. Bethesda (MD): The Institute; [2014]. [cited 2015 Apr 13]. Available from: Johansson K, Neovius K, DeSantis SM, Rossner S, Neovius M. Discontinuation due to adverse events in randomized trials of orlistat, sibutramine and rimonabant: a meta-analysis. Obes Rev. 2009 Sep;10(5):564-75. Bray GA. Medications for weight reduction. Med Clin North Am. 2011 Sep;95(5):989-1008

2015 CADTH - Issues in Emerging Health Technologies

66. Obesity and reproduction: a committee opinion

blocker, was accompanied by suicidal ideation and behavioral changes. Sibutramine, a serotonin- norepinephrine reuptake inhibitor, was linked to myocardial infarction and stroke (138). BariatricSurgery In 2011, over 340,000 bariatric surgical procedures were performedworldwide,withtheUnitedStates/Canadaperform- ing the largest number of operations (over 100,000 cases) (149).Commonbariatricsurgicalproceduresareeitherrestric- tive (i.e., sleeve gastrectomy [SG], laparoscopic adjustable gastric band

2015 Society for Assisted Reproductive Technology

68. Antidepressants for polycystic ovary syndrome. (Abstract)

potential sources of bias.We found no studies reporting any of our primary review outcomes (depression and allied mood disorder scores, quality of life and adverse events). Only one study with 16 women was eligible for inclusion. This study compared sibutramine versus fluoxetine in women with PCOS, and reported only endocrine and metabolic outcomes. It was unclear whether the participants had psychological problems at baseline. No significant difference was found between the groups for any

2013 Cochrane

69. Obesity: European patients protected against lorcaserin, a psychotropic drug sold as an appetite suppressant

) Benfluorex: the appetite- suppressant amphetamine is finally suspended from sale in France (November 2009) Sibutramine: withdrawn from the European market at last! (July 2010) Obesity: diet, physical exercise and support are the priorities (April 2009) Rimonabant: marketing authorisation suspended... at last! Prescrire Int 2009; 18 (100) : 61. | | | Prescrire Your change of address has been received and will be processed promptly but will not appear instantaneously Prescrire Your message has been sent

2014 Prescrire

71. BMI Reduction and Chronic Disease Management

from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Diabetes Obes Metab. 2012 Jun;14(6):523-30. PubMed: PM22192338 20. Shea MK, Nicklas BJ, Houston DK, Miller ME, Davis CC, Kitzman DW, et al. The effect of intentional weight loss on all-cause mortality in older adults: results of a randomized BMI Reduction for Chronic Disease Management 4 controlled weight-loss trial. Am J Clin Nutr [Internet]. 2011 Sep [cited 2014 Apr 16];94(3):839-46. Available from: http://www.ncbi.nlm.nih.gov/pmc

2014 Canadian Agency for Drugs and Technologies in Health - Rapid Review

73. Primary prevention of cardiovascular disease: new guidelines, technologies and therapies Full Text available with Trip Pro

Organisation) diet, have greater weight loss and lower attrition rates in the short term, but longer-term evidence is lacking. Weight-loss medications available to date have been disappointing because of the lack of sustained weight loss and the risk of side effects. Several weight-loss medications have been withdrawn from market due to harmful effects, the most recent being sibutramine. In addition, weight loss achieved using medication is unlikely to have the same health benefits as weight loss achieved (...) . Systematic review of randomized controlled trials of low-carbohydrate vs. low-fat/low-calorie diets in the management of obesity and its comorbidities. Obes Rev 2009; 10: 36-50. Therapeutic Goods Administration. Sibutramine (Reductil) – withdrawal in Australia. 8 Oct 2010. (accessed Feb 2013). National Health and Medical Research Council. Clinical practice guideline for the management of overweight and obesity in adults, adolescents and children in Australia. Public consultation draft — 29 March 2012

2013 MJA Clinical Guidelines

74. Obesity

authorisation for sibutramine (Reductil ® ) because the benefits no longer outweigh the risks. This CKS topic has been updated to reflect the EMEA's decision. Recommendations regarding when to consider prescribing sibutramine as well as its prescribing information and prescriptions have been removed. Issued in January 2010. October 2008 — updated. On 23 October 2008, the EMEA's CMHP recommended the suspension of the marketing authorisation for rimonabant (Acomplia ® ) because the benefits no longer outweigh (...) the risks. This CKS topic has been updated to reflect the EMEA's decision. Recommendations regarding when to consider prescribing rimonabant as well as its prescribing information and prescriptions have been removed. Issued in November 2008. July 2008 — minor update to incorporate the recommendation from NICE that rimonabant may now be prescribed as an alternative to orlistat or sibutramine. A scenario on prescribing rimonabant has been added. May 2008 — minor update to text to reflect updated advice

2017 NICE Clinical Knowledge Summaries

75. Alogliptin and alogliptin/pioglitazone

or substance abuse within the 2 years prior to Screening. • Subject has an active proliferative retinopathy. • Subject has been using medicine for weight loss within one month prior to screening (such as Xenical, Sibutramine, Phenylpropanolamine or similar nonprescription drugs). • Subject has a history of organ transplantation. • The subject is an immediate family member, study site employee, or is in a dependent relationship with a study site employee who is involved in the conduct of this study (e.g

2012 FDA - Drug Approval Package

76. Idebenone Treatment of Early Parkinson's Diseasesymptoms

) Exclusion Criteria: (1)Patients with disturbance of consciousness, aphasia and mental illness; patients with major depression (HAD scale score ≥ 15 points) (2)Patients with Parkinson's superimposition syndrome and patients with secondary Parkinson's syndrome (hepatolenticular degeneration, hepatic encephalopathy, cerebellar disease, hydrocephalus, parathyroid disease, etc.) (3)Patients who have long-term use of dopamine blockers (such as potent neuroleptics, sibutramine, reserpine, metoclopramide, etc

2018 Clinical Trials

77. Lorcaserin and Behavioral Modification for Overweight and Obesity Management in Chinese Obese Patients

(phentermine, sibutramine, orlistat) or lipid dissolving injections within 3 months. Over 3 days of treatment with oral or parenteral corticosteroids within 2 weeks of the screening visit. Recent history (within 2 years prior to the screening visit) of alcohol or drug abuse. Significant change in smoking habits within 3 months prior to screening. Participated in any clinical study with an investigational drug, biologic, or device within 3 month prior to screening. Significant change in diet or level

2018 Clinical Trials

78. Enzyme Kinetics and Molecular Docking Studies on Cytochrome 2B6, 2C19, 2E1, and 3A4 Activities by Sauchinone Full Text available with Trip Pro

key amino acid residues in the active site of CYP2B6, 2C19, 2E1, and 3A4. When sibutramine, clopidogrel, or chlorzoxazone was co-administered with sauchinone to mice, the systemic exposure of each drug was increased compared to that without sauchinone, because sauchinone reduced the metabolic clearance of each drug. In conclusion, when sauchinone was co-treated with drugs metabolized via CYP2B6, 2C19, 2E1, or 3A4, sauchinone-drug interactions occurred because sauchinone inhibited the CYP-mediated

2018 Molecules : A Journal of Synthetic Chemistry and Natural Product Chemistry

79. Pharmacokinetics of Simvastatin Post Laparoscopic Sleeve Gastrectomy (LSG)

, carbamazepine, rifampicin, ketoconazole, fluconazole, itraconazole, voriconanzole, diltiazem, verapamil, dexamethasone, prednisolone, phenytoin, ritonavir, indinavir, nelfinavir, bosentan, telithromycin, nefazodone, St John's wort, orlistat, sibutramine and other strong CYP 3A4 inhibitors/ inducers Pregnant ladies Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using the contact information

2018 Clinical Trials

80. Drugs Involved in Dyslipidemia and Obesity Treatment: Focus on Adipose Tissue Full Text available with Trip Pro

, involved in the pathogenic mechanisms underlying this syndrome. We revised the effects, and underlying mechanisms, of the current approved drugs for dyslipidemia and obesity (fibrates, statins, niacin, resins, ezetimibe, and orlistat; sibutramine; and diethylpropion, phentermine/topiramate, bupropion and naltrexone, and liraglutide) on adipose tissue. Specifically, we explored how these drugs can modulate the complex pathways involved in metabolism, inflammation, atherogenesis, insulin sensitivity

2018 International journal of endocrinology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>